

**MYÉLOME
CANADA**



**MYELOMA
CANADA**

Uniquely devoted to the Canadian myeloma community

Revlimid Provincial Funding Update: December 22, 2010

Nova Scotia and Prince Edward Island remain the only provinces who have not yet approved funding for Revlimid. Quebec and Newfoundland & Labrador will only fund Revlimid as a third-line therapy. All other provinces have approved second-line funding.

Province	Provincial Drug Formulary Status
British Columbia	<p>The BC Cancer Agency (BCCA) is funding for and providing access to Revlimid for treatment of multiple myeloma patients who received at least one prior therapy effective April 1st, 2009, according to eligibility criteria set by the BCCA.</p> <p>Detailed patient eligibility criteria are available on the BCCA website. UMYLENDEX: Therapy of Multiple Myeloma Using Lenalidomide with Dexamethasone</p>
Alberta	<p>The Alberta Cancer Board (ACB) is funding for and providing access to Revlimid for treatment of multiple myeloma patients who received at least one prior therapy effective October 21st, 2009, according to eligibility criteria set by the ACB. Clinical Practice Guidelines citing Revlimid use in multiple myeloma have been released by the Alberta Cancer Board.</p>
Saskatchewan	<p>The Saskatchewan Cancer Agency (SCA) is funding for and providing access to Revlimid for treatment of multiple myeloma patients who received at least one prior therapy effective October 1st, 2009, according to eligibility criteria set by the SCA.</p>
Manitoba	<p>Revlimid was added to the Manitoba Drug Benefits and Interchangeability Formulary Amendments effective September 09, 2010.</p> <p>http://www.gov.mb.ca/health/mdbif/bulletin64.pdf</p>
Ontario	<p>The Ontario Drug Benefit Program is funding for and providing access to Revlimid through the Exceptional Access Program for treatment of multiple myeloma patients who received at least one prior therapy effective, July 24, 2009, according to eligibility criteria set by the ODB.</p> <p>Further details, including side effect information, are available on the Cancer Care Ontario website.</p>

Quebec	<p>The Régie de l'assurance maladie (RAMQ) is funding and providing access to Revlimid through Médicament d'exception effective February 1, 2010.</p> <p>Further details are available on the RAMQ website.</p>
Nova Scotia	<p>Revlimid has been reviewed by the Nova Scotia Cancer Systemic Therapy Policy Committee. The recommendation in January 2009 was to not fund Revlimid. Awaiting further news from the Ministry of Health.</p>
New Brunswick	<p>The New Brunswick Prescription Drug Plan (NBPDP) is funding and providing access to Revlimid for treatment of multiple myeloma patients who received at least one prior therapy effective May 5, 2010, according to eligibility criteria set by the NBPDP.</p> <p>Further details are available on the NBPDP website.</p>
Newfoundland & Labrador	<p>The Newfoundland and Labrador Prescription Drug Plan (NLPDP) is funding and providing access to Revlimid for treatment of multiple myeloma patients effective April 1, 2010, according to eligibility criteria set by the NLPDP.</p> <p>Further details are available on the NLPDP website.</p>
Prince Edward Island	<p>Decision pending. Patients currently have no funded access.</p>